Table 2 IORT studies for renal cancer
Reference | N. pts | Type of cancer | Primary/recurrent | EBRT | IORT dose (Gy) | Technique | Median follow-up | Local control | Overall survival | Toxicity |
|---|---|---|---|---|---|---|---|---|---|---|
Paly [27] | 98 | Advanced or recurrent renal cell carcinoma | Pelvic locally recurrent 100% | 26 pts: 45–40 Gy pre or post surgery | Median dose: 15 Gy (9.5-20 Gy) | IORT | 3.5-years (3–169) | 5-years 39% advanced disease 5-years 52% recurrent disease | 5-years 37% advanced disease 5-years 55% recurrent disease | NA |
Habl [28] | 17 | Locally recurrent disease | Pelvic locally recurrent 100% | - | Median dose: 15 Gy (10–20 Gy) | IORT | 18 months | 2 years 91% | 2 years 73% | No late toxicities |
Calvo [29] | 25 | Advanced or recurrent renal cell carcinoma | Pelvic locally recurrent 100% | 15 pts: 44 Gy perioperative | Median dose: 14 Gy (9–15 Gy) | IORT | 22.2 years (3.6-26) | 5-years 80% | 5-years 38% 10-year 18% | 6 pts acute/late toxicities ≥ 3 |
Hallemeir [30] | 22 | Advanced or recurrent renal cell carcinoma | - | 21 pts: 41.5 Gy perioperative | Median dose: 12.5 Gy (10–20 Gy) | IORT | 9.9 years (3.6-20) | NA | 5-years 40% | 5 ptsacute/late toxicities ≥ 3 |
Master [31] | 14 | Local recurrent renal cell carcinoma | Pelvic locally recurrent 100% | - | Median dose: 15 Gy (12–20 Gy) | IORT | NA | NA | 5 years 30% | NA |
Eble [32] | 14 | Advanced or recurrent renal cell carcinoma | - | 14 pts:40 Gy postoperative | 15-20 Gy | IORT | 24.3 months | NA | 11.5 months | 0% |
Frydenberg [33] | 11 | Local persistence or local recurrent | 11 pts: 45–50.4 Gy preoperative | 10-25 Gy | IORT | NA | NA | NA | NA |